A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival (EFS) and pathologic complete response (pCR) rates compared to chemotherapy alone for patients with operable non-small cell lung cancer (NSCLC), according to results of a Phase III trial reported by...
retrieved 23 October 2023 from https://medicalxpress.com/news/2023-10-lung-cancer-outcomes-significantly-immunotherapy-based.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.Sep 11, 2023 Use this form if you have come across a typo, inaccuracy or would like to send an edit request for the content on this page. For general inquiries, please use ourThank you for taking time to provide your feedback to the editors.
Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.to let the recipient know who sent the email. Neither your address nor the recipient's address will be used for any other purpose. The information you enter will appear in your e-mail message and is not retained by Medical Xpress in any form.Get weekly and/or daily updates delivered to your inbox.
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Pre- and post-surgical immunotherapy improves outcomes for patients with operable lung cancerCompared with pre-surgical (neoadjuvant) chemotherapy alone, adding perioperative immunotherapy—given before and after surgery—significantly improved event-free survival (EFS) in patients with resectable early-stage non-small cell lung cancer (NSCLC).
Read more »
Perioperative immunotherapy improves event-free survival in resectable early-stage lung cancerCompared with pre-surgical (neoadjuvant) chemotherapy alone, adding perioperative immunotherapy – given before and after surgery – significantly improved event-free survival (EFS) in patients with resectable early-stage non-small cell lung cancer (NSCLC).
Read more »
Firms With Nearly $1 Trillion In Revenue Want Timeline For Fossil Fuel Phase-OutAhead of COP28, 131 companies with nearly $1 trillion in global annual revenue have urged national governments to set a timeline for the phaseout of fossil fuels.
Read more »
'Squadron 42 is now feature-complete and has entered its polish phase', says Chris RobertsJody's first computer was a Commodore 64, so he remembers having to use a code wheel to play Pool of Radiance. A former music journalist who interviewed everyone from Giorgio Moroder to Trent Reznor, Jody also co-hosted Australia's first radio show about videogames, Zed Games.
Read more »
Short course of induction chemotherapy can reduce cervical cancer relapse and death by 35%The INTERLACE phase III trial, funded by Cancer Research UK and UCL Cancer Trials Centre, assessed whether a short course of induction chemotherapy (IC) prior to chemoradiation (CRT) could reduce the rate of relapse and death among patients with locally advanced cervical cancer.
Read more »
Belzutifan outperforms everolimus in advanced kidney cancer treatmentBelzutifan significantly reduced the risk of progression of clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer, in patients previously treated with immune checkpoint inhibitors and anti-angiogenic therapies compared with everolimus in a phase 3 clinical trial. The trial, led by Toni K.
Read more »